SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer (SPYX)
SPY-X: A Study to Assess the Feasibility of Using Real-time Fluorescence Lymphangiography Alone for Sentinel Node Localization in Patients With Melanoma or Breast Cancer
Sponsor: Emory University
This PHASE3 trial investigates Breast Cancer and Melanoma (Skin) and is currently completed. Emory University leads this study, which shows 13 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Feb 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 8 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2020 — Sep 2020 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2019 — Feb 2020 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2019 — Nov 2019 [monthly]
Enrolling By Invitation PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
Status: Not Yet Recruiting → Enrolling By Invitation
-
Oct 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- Milton S. Hershey Medical Center
- Vassar Brothers Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .